An interventional study of GPT-Based Digital Assistant in Missed Abortion, Early Pregnancy Loss and Abortion in First Trimester, sponsored by Wolfson Medical Center. Not yet recruiting at 1 site in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Wolfson Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Abortion, Missed with a site in Israel — 2 open to participants now, 2 under way, none of them phase 3. Abortion, Missed · Israel.
Among the 11 studies in Abortion, Missed with a site in Israel, this one is the only one that started in 2026, is one of 6 with no phase, and was the 11th registered.
48 studies on the registry are indexed under Abortion, Missed; 10 are open to participants now.
Browse Abortion, Missed studies →2 of the 11 studies in Abortion, Missed with a site in Israel are open now. Recruiting first, the newest first:
Assaf-Harofeh Medical Center · Sites in Israel
Ages 18–50 · Women only
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 5 Abortion, Missed studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 100 is close to the median of 110 across 41 interventional studies indexed under Abortion, Missed.
Median enrollment 100 across the 9 interventional studies, 110 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 8 most frequent:
Wolfson Medical Center is the lead sponsor of 118 studies on the registry; 17 are open to participants now.
Wolfson Medical Center has 2 studies filed under Abortion, Missed — fewer than ten, so there is no comparison to draw.
1 of the studies in Abortion, Missed with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07856940Wolfson Medical CenterGPT-Based Digital Assistant Support During Treatment for Induced Abortion or Missed Abortion | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Abortion, Missed with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We have developed a digital assistant based on GPT (Generative Pre-trained Transformer) technology, trained specifically to provide empathetic, medically accurate, and guideline-based responses in Hebrew, tailored to the clinical protocols used in our clinic.
The goal of this interventional study is to learn about the feasibility, usability, and acceptability of a GPT-based digital assistant for patients undergoing medication abortion or treatment for missed abortion.
The study aims to assess use of the digital assistant, patient-reported usability, usefulness and satisfaction, perceived support, comprehension of treatment instructions, and decisions about contacting medical staff.
Participants already receiving standard care for medication abortion or missed abortion at the clinic will be offered access to the digital assistant immediately after enrollment. They may use the assistant freely at home throughout their treatment process and will complete baseline and follow-up surveys about their experience, emotional state, and any additional contacts with the clinic.
Medication abortion and treatment for missed abortion can be emotionally and physically demanding experiences. Patients may experience confusion, anxiety, and isolation during the home phase of treatment, and clinical instructions may be difficult to understand or follow during moments of stress or pain. Accessible, timely, and patient-centered information may help support patients throughout this process.
This prospective, single-arm, open-label, interventional feasibility study will assess the feasibility, usability, and acceptability of a GPT-based digital assistant designed to support patients undergoing induced abortion or treatment for missed abortion. The assistant is designed to provide empathetic, guideline-based information in Hebrew, tailored to the clinical protocols used in the clinic. It provides information in plain language and directs patients to the clinic or emergency care when appropriate.
Approximately 100 Hebrew-speaking patients undergoing induced abortion at up to 9 weeks of gestation or treatment for missed abortion at up to 12 weeks of gestation at Wolfson Medical Center will be enrolled during their initial clinic visit. After providing informed consent, participants will receive access to the digital assistant alongside standard clinical care. They may use the assistant as needed throughout the treatment process until the follow-up visit. There is no randomization or comparator group.
Baseline data will include demographic characteristics, previous abortion experience, and expectations regarding the digital assistant. Follow-up data will be collected through a study-specific questionnaire assessing assistant use, ease of use, usefulness, overall satisfaction, self-reported emotional state, perceived support, comprehension of treatment instructions, whether participants contacted medical staff and the type of contact, and whether they decided not to contact medical staff after receiving an answer from the assistant. Open-ended feedback will also be collected.
The study will evaluate feasibility and usage rates, patient satisfaction, perceived emotional support, and comprehension of treatment instructions. Participant feedback will be used to identify opportunities for improvement and explore potential integration into reproductive care.
The assistant is intended to supplement standard clinical information and support, rather than replace professional medical assessment or emergency services. Study data will be anonymized and stored securely in accordance with the approved protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergoing treatment for induced or missed abortion will receive access to a Hebrew-language GPT-based digital assistant upon enrollment, in addition to standard clinical care. Participants may use the assistant as needed until their follow-up visit. The assistant is designed to provide plain-language information about the treatment process, clarify clinical instructions, offer emotional support, and direct participants to the clinic or emergency services when appropriate. It supplements, rather than replaces, professional medical care.
Other: GPT-Based Digital Assistant
a digital assistant based on GPT (Generative Pre-trained Transformer) technology, trained specifically to provide empathetic, medically accurate, and guideline-based responses in Hebrew, tailored to the clinical protocols used in our clinic. The assistant is designed to support patients throughout the medication abortion or missed abortion process, from the time of first medication until the follow-up visit. It offers culturally sensitive information in plain language, referring to the clinic or emergency care as needed.
Feasibility and usage rates of the digital assistant
Feasibility will be assessed by the percentage of follow-up questionnaire respondents who report using the GPT-based digital assistant during the treatment process. Use will be assessed by a yes/no question in the study-specific, non-validated follow-up questionnaire. The number of respondents and the number of enrolled participants without follow-up data will also be reported.
Time frame: From enrollment to follow-up at 2 weeks
Frequency of digital assistant use
Frequency of use will be assessed among participants who report using the GPT-based digital assistant, as assessed using the study-specific, non-validated follow-up questionnaire. Participants select one of four categories: once, 2-3 times, 4-5 times, or more than 5 times. The percentage of users in each category will be reported.
Time frame: From enrollment through follow-up at 2 weeks
Patient satisfaction, usability, and perceived usefulness
Patient experience will be assessed among participants who used the GPT-based digital assistant, using three items in the study-specific, non-validated follow-up questionnaire: ease of use, perceived usefulness of the information, and overall satisfaction. Each item is rated from 1 (do not agree at all) to 5 (strongly agree). Higher scores indicate greater ease of use, usefulness, or satisfaction. Each item will be reported separately; no combined score will be calculated.
Time frame: at 2 weeks after enrollment
Patient-reported decision not to contact medical staff after using the assistant
The percentage of assistant users who report an occasion when they considered contacting medical staff but felt that contact was unnecessary after receiving a response from the GPT-based digital assistant will be assessed using the study-specific, non-validated follow-up questionnaire. Response options are yes, no, and unsure. The distribution of responses will be reported.
Time frame: at 2 weeks after enrollment
Perceived support and availability of answers
Perceived support will be assessed using two items in the study-specific, non-validated questionnaire: having sufficient support to cope with the process, and being able to obtain answers to questions when needed. Each item is rated from 1 (do not agree at all) to 5 (strongly agree), with higher scores indicating greater perceived support or availability of answers. Baseline and follow-up responses will be reported separately for each item.
Time frame: At baseline before first use and at 2 weeks after enrollment.
Self-reported comprehension of treatment instructions
Self-reported comprehension will be assessed using three items in the study-specific, non-validated questionnaire addressing how and when to take medications, expected symptoms, and when to seek medical assistance. Each item is rated from 1 (do not agree at all) to 5 (strongly agree), with higher scores indicating greater perceived comprehension. Baseline and follow-up responses will be reported separately for each item.
Time frame: At baseline before first use and at 2 weeks after enrollment.
Participant suggestions for improvement
Suggestions for improvement will be collected using the open-ended follow-up question asking participants what one thing they would change or improve in the GPT-based digital assistant. Responses will be summarized qualitatively and grouped into recurring themes.
Time frame: at 2 weeks after enrollment
Insights into integration into reproductive care
An exploratory qualitative synthesis of participant suggestions for improvement will identify themes potentially relevant to integrating the digital assistant into routine reproductive care. This assessment will use responses to the open-ended follow-up question asking what participants would change or improve in the assistant and will not generate a numerical score.
Time frame: at 2 weeks after enrollment
Plan to share: No — There is no plan to share individual participant data. Study findings will be disseminated in aggregate form through scientific publications and presentations.
Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.